Sandbox
For pharmaceutical manufacturers with products already on the commercial market, there are limited avenues available to mitigate the immediate business impacts of top-down pricing updates. However, for products currently in the early-to-late development pipeline, policy proposals like the U.S. Most Favored Nation (MFN) pricing model introduce critical strategic considerations that quality, commercialization, and portfolio teams must address immediately.
While the legislative path of MFN proposals—spanning initiatives like the "Generous," "Globe," and "Guard" packages—remains subject to congressional debate, its potential impact on Medicaid, Medicare Part B, and Medicare Part D is so profound that waiting for final passage to plan is a high-risk commercial strategy.
The MFN model proposes capping the maximum reimbursement price for drugs under Medicare and Medicaid in the United States at the lowest GDP-adjusted price observed among a basket of referencing nations. This peer group typically includes Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Ireland, Israel, Italy, Japan, South Korea, Spain, Sweden, Switzerland, and the United Kingdom.
Why MFN Alters Early Development Decisions
The core implication of an MFN system is that drug manufacturers can no longer view international market access in isolation. Previously, setting a lower price in reference countries to secure reimbursement was a common trade-off to capture volume. Under MFN, however, doing so could trigger a direct, downward adjustment of the drug's price in the highly lucrative U.S. market.
Contrary to simplistic policy assumptions, manufacturers cannot easily increase prices in international reference markets to protect their U.S. pricing benchmark. Foreign health authorities utilize strict Health Technology Assessments (HTAs) linked directly to clinical value. To secure higher launch prices abroad, manufacturers will need to provide significantly stronger evidence of value. Achieving this requires increased R&D investments, larger clinical trials, and potentially longer development timelines, which introduces new clinical and regulatory risks.
Strategic Indication Sequencing
The threat of MFN pricing forces a fundamental reassessment of how indications are prioritized during development. Traditionally, the choice of a drug’s initial launch indication is decided based on clinical timelines, probability of success (PoS), development costs, and competitive landscapes. MFN introduces a complex variable: the risk of establishing a low global price benchmark early on that erodes the valuation of future, larger indications.
To navigate this, companies must conduct rigorous scenario mapping. In some cases, launching in a referencing country with a weak initial clinical dossier may not be economically viable, as the resulting U.S. price reduction could wipe out any international revenue gains. Strategic planners must prioritize launching indications with the strongest value propositions first, establishing a robust global price floor before expanding into broader indications.
The Interplay with the Inflation Reduction Act (IRA)
Adding to the complexity of MFN planning is the ongoing implementation of the **Inflation Reduction Act of 2022 (IRA)** in the United States. Under the IRA, the Centers for Medicare & Medicaid Services (CMS) have the authority to select high-spend drugs for price negotiations nine years after FDA approval for small molecules, and 12 years for biologics.
This statutory clock means that manufacturers cannot afford slow, sequential launches across indications. To maximize return on investment before negotiations begin, companies are incentivized to accelerate development timelines so that secondary, high-volume indications follow closely behind the primary launch. This pressure to bundle indications compress clinical development plans and demands highly coordinated regulatory and quality management strategies.
| Strategy Area | Impact of MFN & IRA | Mitigation Approach |
|---|---|---|
| Launch Sequencing | Pre-U.S. international launches can establish a low benchmark, depressing U.S. prices. | Delay referencing launches or prioritize high-price markets (e.g. U.S., Germany, Japan) first. |
| Indication Planning | Early launch of low-value indications permanently lowers the global price ceiling. | Sequence indications with the strongest clinical value and highest price potential first. |
| Clinical Development | IRA clocks start at first approval, compressing the window to launch subsequent indications. | Parallelize Phase III trials to launch multiple indications closely together. |
Conclusion: The Urgency of Portfolio Scenario Analysis
The traditional method of planning drug launches independently by region is no longer viable. MFN and the IRA have unified global pricing, meaning a decision made in Berlin or Tokyo can directly impact revenues in Washington.
To safeguard future portfolios, pharmaceutical developers must embed comprehensive global pricing scenario analyses into their governance gates. Testing commercial strategies against potential MFN thresholds and IRA timelines is no longer just a quality check—it is a baseline requirement for modern drug development survival.
Ed Schoonveld is a leading global value and access advisor, principal at Schoonveld Advisory, LLC, and author of the industry textbook "The Price of Global Health."
